
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4653741/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recurrent Cerebral Infarcts Associated with Uterine Adenomyosis: Successful Prevention by Surgical Removal. Internal Medicine, 2022, 61, 735-738.	0.7	8
2	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 32-40.	1.9	15
3	Nerve Hypertrophy and Altered Diffusion in Anti-Myelin-Associated Glycoprotein Neuropathy Detected by Brachial Plexus Magnetic Resonance Neurography. European Neurology, 2022, 85, 95-103.	1.4	6
4	Isolated spinothalamic sensory impairment of the contralateral lower limb due to lateral medullary infarction. Neurological Sciences, 2022, 43, 725-726.	1.9	1
5	Sixth nerve palsy without other objective neurological deficits due to a small pontine infarction. Acta Neurologica Belgica, 2022, , 1.	1.1	0
6	Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study. JMIR Human Factors, 2022, 9, e26825.	2.0	2
7	Sleep-related hypoventilation and hypercapnia in multiple system atrophy detected by polysomnography with transcutaneous carbon dioxide monitoring. Sleep and Breathing, 2022, 26, 1779-1789.	1.7	3
8	Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19. Internal Medicine, 2022, 61, 1071-1076.	0.7	4
9	A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan. Journal of Epidemiology, 2022, 32, 34-43.	2.4	8
10	Brain 5-HT2A receptor binding and its neural network related to behavioral inhibition system. Brain Imaging and Behavior, 2022, 16, 1337-1348.	2.1	4
11	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
12	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment. Internal Medicine, 2022, 61, 2785-2787.	0.7	4
13	Fatigue and activity-dependent conduction block in neuromuscular disorders. Clinical Neurophysiology Practice, 2022, 7, 71-77.	1.4	2
14	Peripheral-type facial palsy as an initial symptom of lateral medullary infarction. Acta Neurologica Belgica, 2022, , 1.	1.1	0
15	Frontotemporal Brain Sagging Syndrome as a Treatable Cause Mimicking Frontotemporal Dementia: A Case Report. Case Reports in Neurology, 2022, 14, 82-87.	0.7	2
16	Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders. Movement Disorders, 2022, 37, 1235-1244.	3.9	4
17	Ischemic Stroke Due to Metastatic Cervical Bone Tumor: The Importance of â€~Peripheral Vision'. American Journal of Medicine, 2022, 135, e221-e222.	1.5	1
18	Fasciculation intensity and limb dominance in amyotrophic lateral sclerosis: a muscle ultrasonographic study. BMC Neurology, 2022, 22, 85.	1.8	5

#	Article	IF	CITATIONS
19	DRD2 Taq1A Polymorphism-Related Brain Volume Changes in Parkinson's Disease: Voxel-Based Morphometry. Parkinson's Disease, 2022, 2022, 1-7.	1.1	1
20	Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets. Pharmaceuticals, 2022, 15, 433.	3.8	6
21	Different patterns of sensory nerve involvement in chronic inflammatory demyelinating polyneuropathy subtypes. Muscle and Nerve, 2022, 66, 131-135.	2.2	2
22	Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy. Journal of Neuroimmunology, 2022, 365, 577833.	2.3	5
23	Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2022, 113, 131-136.	3.1	6
24	Predicting Outcome in Guillain-Barré Syndrome. Neurology, 2022, 98, .	1.1	22
25	Diagnostic efficacy of the magnetic resonance T1w/T2w ratio for the middle cerebellar peduncle in multiple system atrophy and spinocerebellar ataxia: A preliminary study. PLoS ONE, 2022, 17, e0267024.	2.5	1
26	Microstructural changes in the normal appearance cerebral cortex of multiple sclerosis detected by an advanced diffusion MRI technique. Journal of Neurology, Neurosurgery and Psychiatry, 2022, , jnnp-2021-328089.	1.9	0
27	Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis. JAMA Neurology, 2022, 79, 575.	9.0	24
28	PET-based classification of corticobasal syndrome. Parkinsonism and Related Disorders, 2022, 98, 92-98.	2.2	5
29	Delayed Appearance of Brain Magnetic Resonance Imaging Abnormalities in a Patient with Glial Fibrillary Acidic Protein Astrocytopathy. Internal Medicine, 2022, , .	0.7	Ο
30	Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma. Esophagus, 2022, 19, 617-625.	1.9	1
31	Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome. Bone Marrow Transplantation, 2021, 56, 517-520.	2.4	8
32	Genetic and functional analysis of KIF5A variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 97, 147.e11-147.e17.	3.1	11
33	Magnetic resonance T1w/T2w ratio in the middle cerebellar peduncle might be a sensitive biomarker for multiple system atrophy. European Radiology, 2021, 31, 4277-4284.	4.5	8
34	Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clinical and Experimental Immunology, 2021, 203, 366-374.	2.6	57
35	â€~Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs' by Marsh et al. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 118-119.	1.9	3
36	Anti-MOG antibody–associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 377-383.	1.9	18

#	Article	IF	CITATIONS
37	Lenalidomideâ€associated progressive multifocal leukoencephalopathy. Clinical and Experimental Neuroimmunology, 2021, 12, 63-65.	1.0	2
38	Magnetic resonance neurography in diagnosing childhood chronic inflammatory demyelinating polyradiculoneuropathy. Brain and Development, 2021, 43, 352-356.	1.1	1
39	Facial onset amyotrophic lateral sclerosis with K3E variant in the Cu/Zn superoxide dismutase gene. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 144-146.	1.7	3
40	Changes in serum complements and their regulators in generalized myasthenia gravis. European Journal of Neurology, 2021, 28, 314-322.	3.3	8
41	Cryptococcal Meningitis in a Fingolimod-Treated Patient. Neurology: Clinical Practice, 2021, 11, e549-e550.	1.6	2
42	The Association of Visually Guided Saccades and DAT-SPECT Findings in Parkinson's Disease. European Neurology, 2021, 84, 110-118.	1.4	2
43	Different patterns of brainstem and cerebellar MRI abnormalities in demyelinating disorders with MOG and aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 348-348.	1.9	3
44	Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 473-478.	1.9	4
45	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. EPMA Journal, 2021, 12, 91-101.	6.1	4
46	Dementia and Parkinson-like syndrome with basal ganglia lesion in neuromyelitis optica spectrum disorders. Neurocase, 2021, 27, 223-226.	0.6	3
47	Guillain-Barré syndrome. Lancet, The, 2021, 397, 1214-1228.	13.7	268
48	Long-term outcomes and prognostic factors in generalized myasthenia gravis. Journal of Neurology, 2021, 268, 3781-3788.	3.6	9
49	Dispersion of mean consecutive differences in singleâ€fiber electromyography increases diagnostic sensitivity for myasthenia gravis. Muscle and Nerve, 2021, 63, 885-889.	2.2	3
50	Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 963-968.	1.9	14
51	Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 388-394.	1.7	11
52	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110068.	1.0	6
53	Neuropsychiatric Symptoms in Parkinson's Disease After Subthalamic Nucleus Deep Brain Stimulation. Frontiers in Neurology, 2021, 12, 656041.	2.4	1
54	Methodology for identification of new target molecules in neuroimmunological disorders. Clinical and Experimental Neuroimmunology, 2021, 12, 202-207.	1.0	0

#	Article	IF	CITATIONS
55	Gerstmann's Syndrome in a Patient Double-positive for Antibodies against the N-methyl-D-aspartate Receptor and NH ₂ -terminal of α-enolase. Internal Medicine, 2021, 60, 1463-1468.	0.7	0
56	Electrogastrography for diagnosis of early-stage Parkinson's disease. Parkinsonism and Related Disorders, 2021, 86, 61-66.	2.2	8
57	High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model. NeuroReport, 2021, 32, 803-807.	1.2	1
58	Cerebral large artery stenosis and occlusion in POEMS syndrome. BMC Neurology, 2021, 21, 239.	1.8	2
59	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	5.5	13
60	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1080-1088.	1.9	6
61	Severe orthostatic hypotension associated with lesions of the area postraema in neuromyelitis optica spectrum disorder. ENeurologicalSci, 2021, 23, 100335.	1.3	Ο
62	Coexistence of neuronal intranuclear inclusion disease and amyotrophic lateral sclerosis: an autopsy case. BMC Neurology, 2021, 21, 273.	1.8	8
63	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Journal of the Peripheral Nervous System, 2021, 26, 242-268.	3.1	176
64	Sensory and motor axonal excitability testing in early diabetic neuropathy. Clinical Neurophysiology, 2021, 132, 1407-1415.	1.5	7
65	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. European Neurology, 2021, 84, 435-443.	1.4	5
66	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. European Journal of Neurology, 2021, 28, 3556-3583.	3.3	153
67	Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies. Internal Medicine, 2021, 60, 2671-2675.	0.7	1
68	Characteristics of Early-Onset Dementia in Chiba Prefecture, Japan: A Multicenter Survey. Dementia and Geriatric Cognitive Disorders, 2021, 50, 283-288.	1.5	1
69	Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. Journal of Neurology, 2021, , 1.	3.6	1
70	Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis. JAMA Neurology, 2021, 78, 1153.	9.0	0
71	Effect of racial background on motor cortical function as measured by threshold tracking transcranial magnetic stimulation. Journal of Neurophysiology, 2021, 126, 840-844.	1.8	5
72	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain, 2021, 144, 3392-3404.	7.6	39

#	Article	IF	CITATIONS
73	High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. Journal of Neuroimmunology, 2021, 358, 577634.	2.3	11
74	Intrathymic Plasmablasts Are Affected in Patients With Myasthenia Gravis With Active Disease. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	6
75	Dysfunction of the left angular gyrus may be associated with writing errors in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 267-275.	1.7	7
76	Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1251-1251.	1.9	1
77	Pareidolia in Parkinson's Disease and Multiple System Atrophy. Parkinson's Disease, 2021, 2021, 1-6.	1.1	3
78	Detection of Clonal Plasma Cells in POEMS Syndrome Using Multiparameter Flow Cytometry. Blood, 2021, 138, 2697-2697.	1.4	0
79	Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis. Scandinavian Journal of Immunology, 2021, , e13122.	2.7	1
80	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2020, 26, 128-129.	3.0	4
81	Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome. British Journal of Ophthalmology, 2020, 104, 33-38.	3.9	1
82	Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323.	1.5	63
83	Safety of tapering tacrolimus dose in patients with wellâ€controlled antiâ€acetylcholine receptor antibodyâ€positive myasthenia gravis. European Journal of Neurology, 2020, 27, 100-104.	3.3	7
84	Frequency and features of myasthenia gravis developing after thymectomy. European Journal of Neurology, 2020, 27, 175-180.	3.3	9
85	A model to predict the probability of acute inflammatory demyelinating polyneuropathy. Clinical Neurophysiology, 2020, 131, 63-69.	1.5	2
86	Membrane property changes in most distal motor axons in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2020, 61, 238-242.	2.2	1
87	Standards of instrumentation of EMG. Clinical Neurophysiology, 2020, 131, 243-258.	1.5	109
88	Striatal Encephalitis in Neuropsychiatric Systemic Lupus Erythematosus. Internal Medicine, 2020, 59, 589-590.	0.7	0
89	Determinants of Low Body Mass Index in Patients with Parkinson's Disease: A Multicenter Case-Control Study. Journal of Parkinson's Disease, 2020, 10, 213-221.	2.8	9
90	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 132-139.	1.9	20

#	Article	IF	CITATIONS
91	Increased serum acetylcholine receptor α1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis. Journal of Neuroimmunology, 2020, 339, 577125.	2.3	1
92	Decline in drawing ability and cerebral perfusion in Parkinson's disease patients after subthalamic nucleus deep brain stimulation surgery. Parkinsonism and Related Disorders, 2020, 70, 60-66.	2.2	9
93	Subthalamic Stimulation Inhibits Bladder Contraction by Modulating the Local Field Potential and Catecholamine Level of the Medial Prefrontal Cortex. Frontiers in Neuroscience, 2020, 14, 917.	2.8	3
94	A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Communications Biology, 2020, 3, 526.	4.4	49
95	Serum anti‣RPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	3.9	16
96	Severe worsening of myasthenic symptoms after the eculizumab discontinuation. Journal of Neuroimmunology, 2020, 349, 577424.	2.3	5
97	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1339-1342.	1.9	13
98	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	3.1	15
99	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology, 2020, 202, 239-248.	2.6	6
100	The Neuropsychological Correlates of Brain Perfusion and Gray Matter Volume in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1639-1652.	2.6	3
101	Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study. Clinical and Experimental Immunology, 2020, 202, 321-324.	2.6	3
102	The cerebellar white matter lesions in dentatorubral-pallidoluysian atrophy. Journal of the Neurological Sciences, 2020, 416, 117040.	0.6	7
103	Analysis of Sleep-Related Breathing Disorders in Multiple System Atrophy Via Polysomnography with Transcutaneous Carbon Dioxide Monitoring. , 2020, , .		0
104	Chronic inflammatory demyelinating polyneuropathy and diabetes. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1035-1036.	1.9	5
105	Marked neurological and immunological improvement in refractory eosinophilic granulomatous polyangiitis after treatment with mepolizumab, an antiâ€interleukinâ€5 antibody: A case report. Clinical and Experimental Neuroimmunology, 2020, 11, 181-184.	1.0	1
106	Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies. European Journal of Neurology, 2020, 27, 2658-2661.	3.3	17
107	Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1189-1194.	1.9	15
108	Excitability Properties of Distal Motor Axons in the Human Ulnar Nerve. Neurophysiology, 2020, 52, 134-139.	0.3	0

#	Article	IF	CITATIONS
109	Longâ€term prognosis of Japanese Lambert–Eaton myasthenic syndrome patients with or without small"ell lung carcinoma. Clinical and Experimental Neuroimmunology, 2020, 11, 131-134.	1.0	1
110	Establishment of a clinician-led guideline on the diagnosis and treatment of Hirayama disease using a modified Delphi technique. Clinical Neurophysiology, 2020, 131, 1311-1319.	1.5	26
111	Comparison of brain atrophy in patients with multiple sclerosis treated with first―versus secondâ€generation disease modifying therapy without clinical relapse. European Journal of Neurology, 2020, 27, 2056-2061.	3.3	4
112	ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology, 2020, 94, e1657-e1663.	1.1	39
113	Wall-Eyed Bilateral Internuclear Ophthalmoplegia by Ischemic Stroke. Neurologist, 2020, 25, 82-84.	0.7	7
114	Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners. Neurological Sciences, 2020, 41, 3719-3727.	1.9	5
115	The Relationship Between the Striatal Dopaminergic Neuronal and Cognitive Function With Aging. Frontiers in Aging Neuroscience, 2020, 12, 41.	3.4	16
116	Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. Journal of the Neurological Sciences, 2020, 413, 116771.	0.6	6
117	Hyper-reflexia in Guillain-Barré syndrome: systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 278-284.	1.9	19
118	Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. Journal of Neuroimmunology, 2020, 341, 577170.	2.3	10
119	Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial. Internal Medicine, 2020, 59, 1149-1153.	0.7	9
120	Vertical pons hyperintensity and hot cross bun sign in cerebellar-type multiple system atrophy and spinocerebellar ataxia type 3. BMC Neurology, 2020, 20, 157.	1.8	12
121	Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. ENeurologicalSci, 2020, 19, 100239.	1.3	16
122	Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642090420.	3.5	34
123	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. PLoS ONE, 2020, 15, e0224419.	2.5	11
124	Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 285-290.	1.9	30
125	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Research Protocols, 2020, 9, e17117.	1.0	23
126	Recent topics in inflammatory neuropathies. Clinical and Experimental Neuroimmunology, 2020, 11, 86-87.	1.0	0

#	Article	IF	CITATIONS
127	Different Patterns of Gray Matter Volume Reduction in Early-onset and Late-onset Alzheimer Disease. Cognitive and Behavioral Neurology, 2020, 33, 253-258.	0.9	5
128	Coagulation test and anti-factor Xa activity in patients treated with edoxaban. Nosotchu, 2020, 42, 80-83.	0.1	0
129	Series: Diagnosis at a Glance. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 2411-2413.	0.0	Ο
130	Prodromal muscle cramps predict rapid motor functional decline in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 242-243.	1.9	3
131	Recurrent Neurological Episodes for 10 Years Preceding Skin Lesions in Neuro-Sweet Disease. Internal Medicine, 2019, 58, 3469-3472.	0.7	1
132	Hidden Charcot-Marie-Tooth 1A as Revealed by Peripheral Nerve Imaging. Internal Medicine, 2019, 58, 3157-3161.	0.7	4
133	Changes in nerve excitability indices in hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 9-10.	3.0	2
134	Quantifying iron deposition in the cerebellar subtype of multiple system atrophy and spinocerebellar ataxia type 6 by quantitative susceptibility mapping. Journal of the Neurological Sciences, 2019, 407, 116525.	0.6	16
135	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOC) antibodies determining the optimal method for positivity judgement. Journal of Neuroimmunology, 2019, 336, 577021.	2.3	20
136	Response to "Letter to the editors in regard to the article â€~Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis'― Journal of the Neurological Sciences, 2019, 404, 157-158.	0.6	0
137	Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology, 2019, 93, e975-e983.	1.1	42
138	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
139	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
140	A study supporting possible expression of inwardâ€rectifying potassium channel 2.1 channels in peripheral nerve in a patient with Andersen–Tawil syndrome. Muscle and Nerve, 2019, 59, E28-E30.	2.2	2
141	Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2019, 403, 78-84.	0.6	8
142	Exploring the frequency and clinical background of the "zebra sign―in amyotrophic lateral sclerosis and multiple system atrophy. Journal of the Neurological Sciences, 2019, 401, 90-94.	0.6	5
143	Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. Journal of the Neurological Sciences, 2019, 402, 12-15.	0.6	21
144	Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 981-987.	1.9	143

#	Article	IF	CITATIONS
145	The severity of motor dysfunctions and urinary dysfunction is not correlated in multiple system atrophy. Journal of the Neurological Sciences, 2019, 400, 25-29.	0.6	4
146	Dropped Head in Sporadic Late-onset Nemaline Myopathy. Internal Medicine, 2019, 58, 1967-1968.	0.7	5
147	Improved self-perceived performance for continence problems in patients with Parkinson's disease after deep brain stimulation. Neurology and Clinical Neuroscience, 2019, 7, 51-56.	0.4	1
148	In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Movement Disorders, 2019, 34, 744-754.	3.9	36
149	Response to "regarding the article â€~Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis'― Journal of the Neurological Sciences, 2019, 399, 229.	0.6	0
150	Chronic Inflammatory Demyelinating Polyneuropathy. Advances in Experimental Medicine and Biology, 2019, 1190, 333-343.	1.6	24
151	Diagnostic Challenges Posed by Preceding Peripheral Neuropathy in Very Late-onset Spinocerebellar Ataxia Type 3. Internal Medicine, 2019, 58, 119-122.	0.7	2
152	Increased IP-10 production by blood–nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 444-450.	1.9	8
153	Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. Journal of the Neurological Sciences, 2019, 396, 8-11.	0.6	22
154	An Adult Case of Herpes Simplex Virus-associated Granulomatous Encephalitis. Internal Medicine, 2019, 58, 1491-1494.	0.7	1
155	Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia, 2019, 33, 1723-1735.	7.2	28
156	Atypical chronic inflammatory demyelinating polyneuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 121-121.	1.9	4
157	Proposal of new clinical diagnostic criteria for POEMS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 133-137.	1.9	21
158	VII. Paraneoplastic Neuropathies. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1562-1565.	0.0	0
159	Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731875969.	1.0	14
160	Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. Clinical and Experimental Immunology, 2018, 193, 47-54.	2.6	14
161	Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurology, The, 2018, 17, 519-529.	10.2	111
162	Intravenous versus subcutaneous immunoglobulin – Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	10.2	0

#	Article	IF	CITATIONS
163	Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multiâ€center, openâ€label, 52â€week phase 3 trial. Journal of the Peripheral Nervous System, 2018, 23, 115-119	. 3.1	11
164	Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1539-1548.	2.6	11
165	Worldwide prevalence of neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 555-556.	1.9	87
166	Soluble CD40 ligand disrupts the blood–brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2018, 316, 117-120.	2.3	11
167	In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. Journal of Alzheimer's Disease, 2018, 61, 1037-1052.	2.6	60
168	Chronic inflammatory demyelinating polyneuropathy: The spectrum and immunopathogenesis deciphered by electrophysiology and neuroimaging. Clinical and Experimental Neuroimmunology, 2018, 9, 47-53.	1.0	6
169	Frequency and characteristics of the TBK1 gene variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 64, 158.e15-158.e19.	3.1	15
170	MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism. Parkinsonism and Related Disorders, 2018, 48, 10-16.	2.2	14
171	Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1405-1416.	6.4	80
172	Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood, 2018, 131, 2173-2176.	1.4	36
173	Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. Journal of Neurology, 2018, 265, 1145-1150.	3.6	15
174	Idiopathic cerebellar ataxia (IDCA): Diagnostic criteria and clinical analyses of 63 Japanese patients. Journal of the Neurological Sciences, 2018, 384, 30-35.	0.6	10
175	Reduction of Optic Disc Oedema by Bortezomib and Dexamethasone Followed by Autologous Peripheral Blood Stem Cell Transplantation in Patient with POEMS Syndrome. Neuro-Ophthalmology, 2018, 42, 25-30.	1.0	3
176	The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. Cephalalgia, 2018, 38, 1535-1544.	3.9	10
177	Rapidly progressive Aspergillus meningitis successfully treated with voriconazole and corticosteroids. Neurological Sciences, 2018, 39, 577-579.	1.9	3
178	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 385, 64-68.	0.6	10
179	Clinical and magnetic resonance imaging features of elderly onset dentatorubral–pallidoluysian atrophy. Journal of Neurology, 2018, 265, 322-329.	3.6	19
180	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	10.2	193

#	Article	IF	CITATIONS
181	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	1.8	38
182	Urinary symptoms are correlated with quality of life after deep brain stimulation in Parkinson's disease. Brain and Behavior, 2018, 8, e01164.	2.2	9
183	Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2018, 325, 54-60.	2.3	17
184	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Frontiers in Neurology, 2018, 9, 888.	2.4	194
185	Reversal of pulmonary arterial hypertension in POEMS syndrome with thalidomide: a case report. European Heart Journal - Case Reports, 2018, 2, yty051.	0.6	Ο
186	Regional variation of Guillain-Barré syndrome. Brain, 2018, 141, 2866-2877.	7.6	190
187	The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand?. Clinical Neurophysiology, 2018, 129, 2586-2593.	1.5	73
188	Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1082-1087.	1.9	30
189	Spinal myoclonus selectively affecting the platysma after cervical laminectomy. Neurology, 2018, 91, 45-46.	1.1	1
190	Clonal immunoglobulin λ lightâ€chain gene rearrangements detected by next generation sequencing in POEMS syndrome. American Journal of Hematology, 2018, 93, 1161-1168.	4.1	9
191	Teaching NeuroImages: Cerebral cortex swelling in Creutzfeldt-Jakob disease with V180I mutation. Neurology, 2018, 91, e185-e186.	1.1	4
192	Isolated iliopsoas paresis due to traumatic cortical hemorrhage. Neurological Sciences, 2018, 39, 1297-1298.	1.9	0
193	Bilateral spinal anterior horn lesions in acute motor axonal neuropathy. Brain and Development, 2018, 40, 830-832.	1.1	1
194	MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 900-900.	1.9	4
195	Meningitis-retention syndrome: Clinical features, frequency and prognosis. Journal of the Neurological Sciences, 2018, 390, 261-264.	0.6	14
196	Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1208-1214.	1.9	30
197	Novel mutations in the ALDH18A1 gene in complicated hereditary spastic paraplegia with cerebellar ataxia and cognitive impairment. Journal of Human Genetics, 2018, 63, 1009-1013.	2.3	18
198	I. Immune-mediated neuropathies. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1457-1461.	0.0	0

#	Article	IF	CITATIONS
199	The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e12046.	1.0	3
200	Adequate tacrolimus concentration for myasthenia gravis treatment. European Journal of Neurology, 2017, 24, 270-275.	3.3	29
201	Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [¹¹ C]PBB3â€PET study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 11-20.	2.4	66
202	Changes in subfoveal choroidal thickness and reduction of serum levels of vascular endothelial growth factor in patients with POEMS syndrome. British Journal of Ophthalmology, 2017, 101, 786-790.	3.9	11
203	Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. Journal of Neuroimmunology, 2017, 305, 131-134.	2.3	5
204	Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 459-459.	1.9	9
205	Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis. Clinical Neurophysiology, 2017, 128, 1176-1183.	1.5	90
206	International Guillainâ€Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillainâ€Barré syndrome. Journal of the Peripheral Nervous System, 2017, 22, 68-76.	3.1	89
207	Post-Polio-Like Syndrome. American Journal of Medicine, 2017, 130, e491-e492.	1.5	1
208	Long term follow-up on quality of life and its relationship to motor and cognitive functions in Parkinson's disease after deep brain stimulation. Journal of the Neurological Sciences, 2017, 379, 18-21.	0.6	16
209	Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 620-620.	1.9	0
210	Pain-related evoked potentials after intraepidermal electrical stimulation to Aδ and C fibers in patients with neuropathic pain. Neuroscience Research, 2017, 121, 43-48.	1.9	27
211	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clinica Chimica Acta, 2017, 469, 144-149.	1.1	32
212	Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2017, 305, 102-107.	2.3	35
213	Neuroimmunology of a natural disaster. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 283-283.	1.9	2
214	Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 266-271.	1.9	87
215	Safety and Efficacy of Granulocyte Colony–Stimulating Factor Monotherapy for Peripheral Blood Stem Cell Collection in POEMS Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 361-363.	2.0	9
216	Serum cytokine and chemokine profiles in patients with juvenile muscular atrophy of distal upper extremity (Hirayama disease). Journal of Neuroimmunology, 2017, 302, 20-22.	2.3	3

#	Article	IF	CITATIONS
217	A clinical predictive score for postoperative myasthenic crisis. Annals of Neurology, 2017, 82, 841-849.	5.3	27
218	Markers for Guillainâ€Barré syndrome with poor prognosis: a multi enter study. Journal of the Peripheral Nervous System, 2017, 22, 433-439.	3.1	46
219	Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson's disease: A multicenter case-controlled study. Parkinsonism and Related Disorders, 2017, 44, 18-22.	2.2	20
220	Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 953-959.	1.9	48
221	Postvoid residual predicts the diagnosis of multiple system atrophy in Parkinsonian syndrome. Journal of the Neurological Sciences, 2017, 381, 230-234.	0.6	18
222	Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 832-838.	1.9	45
223	MR Imaging Features of the Cerebellum in Adult-Onset Neuronal Intranuclear Inclusion Disease: 8 Cases. American Journal of Neuroradiology, 2017, 38, 2100-2104.	2.4	65
224	[ICâ€Pâ€198]: FIRSTâ€INâ€HUMAN PET STUDY WITH ¹⁸ Fâ€AMâ€PBB3 AND ¹⁸ Fâ€PMa Alzheimer's and Dementia, 2017, 13, P146.	â€₽₿₿3. 0.8	10
225	[P3–495]: INTRODUCING THE ASSOCIATION BETWEEN CHILDREN AND DEMENTED ELDERLY (ABCDE) PROJECT Alzheimer's and Dementia, 2017, 13, P1165.	·0.8	0
226	Headache attributed to aeroplane travel and reversible cerebral vasoconstriction syndrome. Cephalalgia, 2017, 37, 1310-1310.	3.9	3
227	Reversible cerebral vasoconstriction syndrome precipitated by airplane descent: Case report. Cephalalgia, 2017, 37, 1102-1105.	3.9	11
228	A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells. Neurotherapeutics, 2017, 14, 191-198.	4.4	6
229	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood–brain barrier disruption. Multiple Sclerosis Journal, 2017, 23, 1072-1084.	3.0	48
230	Electrophysiology in Fisher syndrome. Clinical Neurophysiology, 2017, 128, 215-219.	1.5	20
231	Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis. Internal Medicine, 2017, 56, 2865-2869.	0.7	4
232	Identification of Serum Anti-GADD34 Antibody as a Common Marker of Diabetes Mellitus and Parkinson Disease. , 2017, 07, .		5
233	The Utility of Post-Void Residual Volume versus Sphincter Electromyography to Distinguish between Multiple System Atrophy and Parkinson's Disease. PLoS ONE, 2017, 12, e0169405.	2.5	17
234	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. PLoS ONE, 2017, 12, e0184012.	2.5	10

#	Article	IF	CITATIONS
235	Diffuse Cerebral Vasoconstriction in a Intravascular Lymphoma Patient with a High Serum MPO-ANCA Level. Internal Medicine, 2017, 56, 1715-1718.	0.7	7
236	Brain gray matter structural network in myotonic dystrophy type 1. PLoS ONE, 2017, 12, e0187343.	2.5	15
237	Genetic Screening for Spinocerebellar Ataxia Genes in a Japanese Single-Hospital Cohort. Journal of Movement Disorders, 2017, 10, 116-122.	1.3	6
238	Severe Subcutaneous Calcification in an Interferon-β-treated MS Patient. Internal Medicine, 2017, 56, 879-880.	0.7	1
239	Pontine Syphilitic Gumma in an HIV-negative Patient. Internal Medicine, 2017, 56, 1747-1748.	0.7	2
240	Discussion on Clinical Diversity of Various Encephalitis/Encephalopathy. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1598-1610.	0.0	0
241	Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD). PLoS ONE, 2016, 11, e0167473.	2.5	7
242	How often and when Fisher syndrome is overlapped by Guillainâ€Barré syndrome or Bickerstaff brainstem encephalitis?. European Journal of Neurology, 2016, 23, 1058-1063.	3.3	46
243	Urinary Dysfunctions Are More Severe in the Parkinsonian Phenotype of Multiple System Atrophy. Movement Disorders Clinical Practice, 2016, 3, 275-281.	1.5	8
244	Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. European Journal of Neurology, 2016, 23, 276-281.	3.3	30
245	Bilateral Foot Acrocyanosis in an Interferon-β-treated MS Patient. Internal Medicine, 2016, 55, 319-319.	0.7	4
246	Progressive Multifocal Leukoencephalopathy Localized in the Cerebellum and Brainstem Associated with Idiopathic CD4 ⁺ T Lymphocytopenia. Internal Medicine, 2016, 55, 1645-1647.	0.7	13
247	Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 821-830.	1.9	61
248	Case of Morvan syndrome with antiâ€Ma2/Ta antibodies. Clinical and Experimental Neuroimmunology, 2016, 7, 369-372.	1.0	3
249	HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. Journal of the Neurological Sciences, 2016, 363, 116-118.	0.6	21
250	Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2016, 263, 1129-1136.	3.6	25
251	Acutely deteriorated extravascular volume overload during peripheral blood stem cell mobilization in POEMS syndrome: A case series with cytokine analysis. Transfusion and Apheresis Science, 2016, 54, 276-281.	1.0	3
252	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691.	1.5	74

#	Article	IF	CITATIONS
253	Pneumocephalus associated with Pott's puffy tumor. Journal of the Neurological Sciences, 2016, 362, 196-197.	0.6	5
254	Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2016, 15, 1129-1137.	10.2	66
255	Increased motor axonal persistent sodium currents predict rapid functional declines in amyotrophic lateral sclerosis. Neurology and Clinical Neuroscience, 2016, 4, 108-111.	0.4	9
256	Reversible Cerebral Vasoconstriction Syndrome with Transient Splenial Lesions after Delivery. Internal Medicine, 2016, 55, 3357-3359.	0.7	5
257	Dorsal horn interneuron-derived Netrin-4 contributes to spinal sensitization in chronic pain via Unc5B. Journal of Experimental Medicine, 2016, 213, 2949-2966.	8.5	12
258	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. Journal of the Neurological Sciences, 2016, 367, 375-379.	0.6	16
259	Utility of ultrasonography in evaluating muscle contractions in stiff-person syndrome. Journal of the Neurological Sciences, 2016, 367, 361-362.	0.6	3
260	Changes in inflammatory cytokine networks in myasthenia gravis. Scientific Reports, 2016, 6, 25886.	3.3	37
261	Future treatment for Guillain–Barré syndrome. Clinical and Experimental Neuroimmunology, 2016, 7, 320-323.	1.0	5
262	Relationship between damage-associated molecular patterns and cytokines in myasthenia gravis. Clinical and Experimental Neuroimmunology, 2016, 7, 357-360.	1.0	0
263	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2016, 453, 131-133.	1.1	10
264	POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification. Orphanet Journal of Rare Diseases, 2016, 11, 35.	2.7	12
265	Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome. British Journal of Ophthalmology, 2016, 100, 897-901.	3.9	16
266	Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiology of Aging, 2016, 39, 219.e1-219.e8.	3.1	49
267	Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2016, 7, 52-58.	1.0	8
268	Demyelinating Guillain-Barré syndrome recurs more frequently than axonal subtypes. Journal of the Neurological Sciences, 2016, 365, 132-136.	0.6	8
269	A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of <i>TTN</i> . Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 851-858.	1.9	33
270	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Multiple Sclerosis Journal, 2016, 22, 1371-1375.	3.0	9

#	Article	IF	CITATIONS
271	Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders. PLoS ONE, 2016, 11, e0149278.	2.5	25
272	Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis. PLoS ONE, 2016, 11, e0158596.	2.5	36
273	A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols, 2016, 5, e210.	1.0	18
274	POEMS Syndrome. , 2016, , 203-210.		0
275	Clonal Immunoglobulin λ Light-Chain Gene Rearrangements Detected By Next Generation Sequencing in POEMS Syndrome. Blood, 2016, 128, 4405-4405.	1.4	0
276	Distinctive Genetic Features of Plasma Cells in POEMS Syndrome. Blood, 2016, 128, 4404-4404.	1.4	0
277	The role of granulocyteâ€macrophage colonyâ€stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?. Clinical and Experimental Neuroimmunology, 2015, 6, 70-77.	1.0	Ο
278	Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open, 2015, 5, e009157-e009157.	1.9	53
279	Primary Cerebral Lymphomatoid Granulomatosis Progressing to Methotrexate-associated Lymphoproliferative Disease Under Immunosuppressive Therapy. Internal Medicine, 2015, 54, 503-507.	0.7	9
280	Brachial Plexus Involvement of Myeloid Sarcoma Detected by Reconstruction Magnetic Resonance Neurography. Internal Medicine, 2015, 54, 2251-2253.	0.7	2
281	Dementia with Lewy bodies can be wellâ€differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity—a [¹¹ C]MP4A PET study. International Journal of Geriatric Psychiatry, 2015, 30, 1105-1113.	2.7	30
282	Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring. British Journal of Clinical Pharmacology, 2015, 80, 607-608.	2.4	3
283	Combined nerve/muscle/skin biopsy could increase diagnostic sensitivity for vasculitic neuropathy. Clinical and Experimental Neuroimmunology, 2015, 6, 312-317.	1.0	8
284	Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient. Clinical and Experimental Neuroimmunology, 2015, 6, 299-303.	1.0	1
285	Reconstruction magnetic resonance neurography clearly shows distribution of nerve enlargement in chronic inflammatory demyelinating polyneuropathy. Clinical and Experimental Neuroimmunology, 2015, 6, 113-113.	1.0	Ο
286	Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 409-412.	1.0	5
287	Myocardial ¹²³ I-MIBG Uptake and Cardiovascular Autonomic Function in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-5.	1.1	9
288	Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0138462.	2.5	7

#	Article	IF	CITATIONS
289	Abnormal gating of axonal slow potassium current in cramp-fasciculation syndrome. Clinical Neurophysiology, 2015, 126, 1246-1254.	1.5	11
290	Altered axonal excitability properties and nerve edema in POEMS syndrome. Clinical Neurophysiology, 2015, 126, 2014-2018.	1.5	6
291	Cryptococcosis mimicking lung cancer with brain metastasis. Clinical Neurology and Neurosurgery, 2015, 135, 93-95.	1.4	10
292	Transient global amnesia with a hippocampal lesion followed by transient epileptic amnesia. Seizure: the Journal of the British Epilepsy Association, 2015, 31, 141-143.	2.0	13
293	Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2015, 279, 7-10.	2.3	40
294	Putaminal hypointensity on T2*-weighted MR imaging is the most practically useful sign in diagnosing multiple system atrophy: A preliminary study. Journal of the Neurological Sciences, 2015, 349, 174-178.	0.6	21
295	A multicentre prospective study of Guillain-Barré Syndrome in Japan: a focus on the incidence of subtypes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 110-114.	1.9	49
296	Moesin, membraneâ€organizing extension spike protein, is a possible immunological target in Guillain–Barré syndrome after cytomegalovirus infection. Clinical and Experimental Neuroimmunology, 2015, 6, 5-6.	1.0	0
297	Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. Journal of Neurology, 2015, 262, 1019-1023.	3.6	23
298	Nodopathies of the peripheral nerve: an emerging concept. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1186-1195.	1.9	120
299	Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open, 2015, 5, e007330-e007330.	1.9	14
300	Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 230-236.	1.7	76
301	Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2015, 287, 9-15.	2.3	5
302	Incidental diagnosis of an asymptomatic adult-onset Alexander disease by brain magnetic resonance imaging for preoperative evaluation. Journal of the Neurological Sciences, 2015, 354, 131-132.	0.6	15
303	Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. Journal of the Neurological Sciences, 2015, 355, 147-149.	0.6	14
304	Muscle haematoma due to antithrombotic treatment for ischaemic stroke. Journal of Clinical Neuroscience, 2015, 22, 1160-1163.	1.5	5
305	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. Journal of Neuroimmunology, 2015, 284, 30-36.	2.3	28
306	Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese–European multicenter prospective study. Clinical Neurophysiology, 2015, 126, 1805-1810.	1.5	24

#	Article	IF	CITATIONS
307	Serum high mobility group box 1 is upregulated in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 695-697.	1.9	21
308	Variants associated with Gaucher disease in multiple system atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 417-426.	3.7	90
309	Metronidazole-induced encephalopathy with contrast enhancing lesions on MRI. Journal of the Neurological Sciences, 2015, 352, 129-131.	0.6	10
310	Paranodal destruction and axo-glial dysjunction in a subtype of CIDP with anticontaction-1 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 707-707.	1.9	3
311	Correlation between serum level of vascular endothelial growth factor and subfoveal choroidal thickness in patients with POEMS syndrome. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1641-1646.	1.9	14
312	Skin sympathetic function in complex regional pain syndrome type 1. Clinical Autonomic Research, 2015, 25, 367-371.	2.5	2
313	Epstein-Barr virus persistence and reactivation in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1137-1142.	1.9	31
314	Increased serum peroxiredoxin 5 levels in myasthenia gravis. Journal of Neuroimmunology, 2015, 287, 16-18.	2.3	11
315	A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 353-358.	1.7	42
316	Benign neuromyelitis optica is rare in Japanese patients. Multiple Sclerosis Journal, 2015, 21, 1204-1208.	3.0	4
317	Corticosteroid-responsive leptomeningitis with IgG4-positive plasma-cell infiltration. Journal of the Neurological Sciences, 2015, 357, 338-340.	0.6	9
318	Recurrent, alternating orbital inflammation. Journal of the Neurological Sciences, 2015, 357, 288-289.	0.6	0
319	Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 2015, 77, 333-337.	5.3	103
320	Delayed facial weakness in Guillain-Barré and miller fisher syndromes. Muscle and Nerve, 2015, 51, 811-814.	2.2	21
321	Different electrophysiological profiles and treatment response in â€~typical' and â€~atypical' chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1054-1059.	1.9	95
322	Acquired and genetic channelopathies: In vivo assessment of axonal excitability. Experimental Neurology, 2015, 263, 368-371.	4.1	4
323	Current symptomatology in multiple sclerosis and neuromyelitis optica. European Journal of Neurology, 2015, 22, 299-304.	3.3	25
324	Severity and Patterns of Blood-Nerve Barrier Breakdown in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Correlations with Clinical Subtypes. PLoS ONE, 2014, 9, e104205.	2.5	44

#	Article	IF	CITATIONS
325	Wound Complications of the Retroperitoneal Approach for the Abdominal Aortic Aneurysm Repair—An Evaluation of Abdominal Bulge Formation—. Annals of Vascular Diseases, 2014, 7, 17-20.	0.5	2
326	Antemortem detection of colonic α-synuclein pathology in a patient with pure autonomic failure. Journal of Neurology, 2014, 261, 2451-2452.	3.6	8
327	Spreading of amyotrophic lateral sclerosis lesionsmultifocal hits and local propagation?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 85-91.	1.9	68
328	Exercise, dominant hand and neurodegeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1291-1291.	1.9	0
329	Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1180-1180.	1.9	5
330	Apathy correlates with prefrontal amyloid deposition in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 449-455.	1.9	97
331	Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 218-220.	3.0	6
332	Multiple enhancing brain lesions after discontinuation of fingolimod in a patient with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 52-53.	1.0	0
333	Time-dependent changes and gender differences in urinary dysfunction in patients with multiple system atrophy. Neurourology and Urodynamics, 2014, 33, 516-523.	1.5	21
334	Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2014, 178, 245-252.	2.6	14
335	Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clinical and Experimental Immunology, 2014, 176, 232-237.	2.6	64
336	Duration of the Distal Compound Muscle Action Potential for Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Clinical Neurophysiology, 2014, 31, 441-443.	1.7	1
337	Involvement of group Ia afferents in Fisher syndrome: Neuronopathy or axonopathy?. Clinical Neurophysiology, 2014, 125, 213-214.	1.5	1
338	Fasciculations, axonal hyperecitability, and motoneuronal death in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2014, 125, 872-873.	1.5	11
339	Isolated transient myoclonus in the elderly: An under-recognized condition?. Clinical Neurology and Neurosurgery, 2014, 117, 51-54.	1.4	6
340	Direct application of MALDI-TOF mass spectrometry to cerebrospinal fluid for rapid pathogen identification in a patient with bacterial meningitis. Clinica Chimica Acta, 2014, 435, 59-61.	1.1	78
341	Neuromyelitis optica: Concept, immunology and treatment. Journal of Clinical Neuroscience, 2014, 21, 12-21.	1.5	48
342	Guillain-Barre syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 907-913.	1.9	63

#	Article	IF	CITATIONS
343	"Bright spotty lesions―on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 331-337.	3.0	104
344	Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology, 2014, 83, 113-117.	1.1	56
345	Effects of diet-induced obesity and voluntary exercise in a tauopathy mouse model: Implications of persistent hyperleptinemia and enhanced astrocytic leptin receptor expression. Neurobiology of Disease, 2014, 71, 180-192.	4.4	41
346	Vogt–Koyanagi–Harada disease with meningitis-retention syndrome and increased CSF adenosine deaminase levels. Clinical Neurology and Neurosurgery, 2014, 127, 42-43.	1.4	8
347	A 3-year cohort study of the natural history of spinocerebellar ataxia type 6 in Japan. Orphanet Journal of Rare Diseases, 2014, 9, 118.	2.7	35
348	Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications. Brain Pathology, 2014, 24, 67-73.	4.1	79
349	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathologica, 2014, 128, 423-437.	7.7	203
350	A case of fulminant neuromyelitis optica presenting with destructive lesions in whole-brain. Clinical Neurology and Neurosurgery, 2014, 116, 87-89.	1.4	2
351	Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology, 2014, 83, 118-124.	1.1	38
352	Reply to letter to the Editor: Isolated transient myoclonus in the elderly. Clinical Neurology and Neurosurgery, 2014, 120, 142.	1.4	0
353	First adult case of Helicobacter cinaedi meningitis. Journal of the Neurological Sciences, 2014, 336, 263-264.	0.6	20
354	The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation. Neuroscience, 2014, 259, 43-52.	2.3	11
355	Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy. Clinical Neurophysiology, 2014, 125, 381-387.	1.5	25
356	Immunohistochemical analysis of tau phosphorylation and astroglial activation with enhanced leptin receptor expression in diet-induced obesity mouse hippocampus. Neuroscience Letters, 2014, 571, 11-16.	2.1	38
357	Voltage-gated Potassium Channel Antibody-associated Encephalitis with Claustrum Lesions. Internal Medicine, 2014, 53, 2263-2264.	0.7	9
358	Nasu-Hakola Disease Revealed on X-ray. Internal Medicine, 2014, 53, 2407-2407.	0.7	1
359	Sudomotor and Cardiovascular Dysfunction in Patients with Early Untreated Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 385-393.	2.8	25
360	Safety and Efficacy of Intravenous Ultra-high Dose Methylcobalamin Treatment for Peripheral Neuropathy: A Phase I/II Open Label Clinical Trial. Internal Medicine, 2014, 53, 1927-1931.	0.7	18

#	Article	IF	CITATIONS
361	Steroid-Responsive Epilepsia Partialis Continua with Anti-Thyroid Antibodies: A Spectrum of Hashimoto's Encephalopathy. Case Reports in Neurology, 2014, 6, 166-170.	0.7	5
362	Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy. Journal of Neurology, 2013, 260, 475-483.	3.6	18
363	Bickerstaff brainstem encephalitis: more common than we think?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1184-1184.	1.9	4
364	Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurology, The, 2013, 12, 1180-1188.	10.2	244
365	CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 517-522.	1.9	44
366	Somatotopic representation of pain in the primary somatosensory cortex (S1) in humans. Clinical Neurophysiology, 2013, 124, 1422-1430.	1.5	39
367	Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clinica Chimica Acta, 2013, 421, 181-183.	1.1	74
368	Patterns of sensory nerve conduction abnormalities in Fisher syndrome: More predominant involvement of group Ia afferents than skin afferents. Clinical Neurophysiology, 2013, 124, 1465-1469.	1.5	29
369	Skin temperature of the hand in multiple system atrophy and Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 560-562.	2.2	11
370	Retinol palmitate prevents ischemia-induced cell changes in hippocampal neurons through the Notch1 signaling pathway in mice. Experimental Neurology, 2013, 247, 182-187.	4.1	4
371	Multiple mechanisms for distal axonal loss in Guillain-Barré syndrome. Clinical Neurophysiology, 2013, 124, 821-822.	1.5	4
372	Isolated ocular flutter. Neurology, 2013, 80, 867-867.	1.1	1
373	Multiple angiogenetic factors are upregulated in POEMS syndrome. Annals of Hematology, 2013, 92, 245-248.	1.8	30
374	Reply to "Serial electrodiagnostic studies increase the diagnostic yield of axonal Guillain–Barré syndrome― Clinical Neurophysiology, 2013, 124, 212-213.	1.5	1
375	Prominent fatigue in spinal muscular atrophy and spinal and bulbar muscular atrophy: Evidence of activity-dependent conduction block. Clinical Neurophysiology, 2013, 124, 1893-1898.	1.5	26
376	Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1346-1348.	1.9	57
377	Seasonality of multiple sclerosis and neuromyelitis optica exacerbations in Japan. Multiple Sclerosis Journal, 2013, 19, 378-379.	3.0	11
378	Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Multiple Sclerosis Journal, 2013, 19, 308-315.	3.0	35

#	Article	IF	CITATIONS
379	Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 969-972.	1.9	71
380	Is â€~Bickerstaff brainstem encephalitis' really encephalitis?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 712-712.	1.9	5
381	Role of interleukinâ€6 in the pathogenesis of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 167-172.	1.0	8
382	Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines: The risks and benefits. Clinical and Experimental Neuroimmunology, 2013, 4, 249-250.	1.0	0
383	Upbeat nystagmus at caudal brainstem lesions in four cases with multiple sclerosis and its related disorders. Clinical and Experimental Neuroimmunology, 2013, 4, 206-209.	1.0	1
384	Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (<scp>C</scp> row– <scp>F</scp> ukase) syndrome: Diagnostic criteria and treatment perspectives. Clinical and Experimental Neuroimmunology, 2013, 4, 318-325.	1.0	18
385	Diagnostic spectrum of multifocal motor neuropathy. Clinical and Experimental Neuroimmunology, 2013, 4, 210-215.	1.0	1
386	POEMS syndrome and interleukinâ€12: <scp>M</scp> issing piece in the pathogenesis of peripheral nerve demyelination. Clinical and Experimental Neuroimmunology, 2013, 4, 16-17.	1.0	0
387	Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2013, 172, 37-43.	2.6	44
388	Environment surrounding the ganglioside clusters as immunological targets in <scp>G</scp> uillain– <scp>B</scp> arré syndrome. Clinical and Experimental Neuroimmunology, 2013, 4, 10-11.	1.0	0
389	Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 398-401.	1.9	69
390	Cervical Myelopathy in Patients With Athetoid Cerebral Palsy. Spine, 2013, 38, E151-E157.	2.0	15
391	βâ€∎myloid in lewy body disease is related to Alzheimer's diseaseâ€like atrophy. Movement Disorders, 2013, 28, 169-175.	3.9	58
392	Acute Brachial Plexopathy Caused by Burkitt's Lymphoma Infiltration. Internal Medicine, 2013, 52, 931-931.	0.7	4
393	Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Baló's Concentric Lesions. Internal Medicine, 2013, 52, 1517-1521.	0.7	22
394	Immune-mediated neuropathies induced by immunosuppressive treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 672-672.	1.9	0
395	Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 734-738.	1.9	97
396	CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 339-340.	1.9	41

#	Article	IF	CITATIONS
397	Ultrasonographic Detection of Fasciculations Markedly Increases Diagnostic Sensitivity of ALS. Neurology, 2012, 78, 370-371.	1.1	11
398	Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain, 2012, 135, 833-846.	7.6	91
399	Mobilization of PBSCs in poor mobilizers with POEMS syndrome using C-CSF with plerixafor. Bone Marrow Transplantation, 2012, 47, 1587-1588.	2.4	10
400	Antiganglioside antibodies are associated with axonal Guillain–Barré syndrome: A Japanese–Italian collaborative study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 23-28.	1.9	108
401	Pentanucleotide repeat-primed PCR for genetic diagnosis of spinocerebellar ataxia type 31. Journal of Human Genetics, 2012, 57, 807-808.	2.3	13
402	A Case of Adult-Onset Alexander Disease Featuring Severe Atrophy of the Medulla Oblongata and Upper Cervical Cord on Magnetic Resonance Imaging. Case Reports in Neurology, 2012, 4, 202-206.	0.7	6
403	Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. Brain, 2012, 135, 1478-1485.	7.6	89
404	Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology, 2012, 79, 575-582.	1.1	81
405	A Case of Primary Central Nervous System Lymphoma Presenting Diffuse Infiltrative Luekoencephalopathy. Internal Medicine, 2012, 51, 1103-1106.	0.7	6
406	Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 476-479.	1.9	147
407	When is neuromyelitis optica diagnosed after disease onset?. Journal of Neurology, 2012, 259, 1600-1605.	3.6	11
408	The split hand syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 399-403.	1.9	132
409	Anti-N-methyl d-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis. Clinical Neurology and Neurosurgery, 2012, 114, 402-404.	1.4	20
410	Awaji ALS criteria increase the diagnostic sensitivity in patients with bulbar onset. Clinical Neurophysiology, 2012, 123, 382-385.	1.5	53
411	The motor nerve terminals, as the barrier-free targets in immune-mediated neuropathies. Clinical Neurophysiology, 2012, 123, 219-220.	1.5	3
412	Reference values for voluntary and stimulated single-fibre EMG using concentric needle electrodes: A multicentre prospective study. Clinical Neurophysiology, 2012, 123, 613-620.	1.5	41
413	Clinical neurophysiology and immunology of E–C coupling of muscle. Clinical Neurophysiology, 2012, 123, 1065-1066.	1.5	0
414	Differences in excitability between median and superficial radial sensory axons. Clinical Neurophysiology, 2012, 123, 1440-1445.	1.5	5

#	Article	IF	CITATIONS
415	Electrodiagnostic criteria for Guillain–BarrÃ syndrome: A critical revision and the need for an update. Clinical Neurophysiology, 2012, 123, 1487-1495.	1.5	214
416	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. The Cochrane Library, 2012, , CD006828.	2.8	53
417	Clinical features and recovery patterns of acquired non-thyrotoxic hypokalemic paralysis. Journal of the Neurological Sciences, 2012, 313, 42-45.	0.6	7
418	Preserved autonomic function in patients with POEMS syndrome. Journal of the Neurological Sciences, 2012, 318, 131-134.	0.6	9
419	Cutaneous Sympathetic Dysfunction in Patients with Machado–Joseph Disease. Cerebellum, 2012, 11, 1057-1060.	2.5	7
420	Factors associated with the efficiency of PBSC collection in POEMS syndrome patients undergoing autologous PBSC transplantation. Bone Marrow Transplantation, 2012, 47, 1010-1012.	2.4	10
421	Flattened facial colliculus on magnetic resonance imaging in Machado–Joseph disease. Movement Disorders, 2012, 27, 1041-1046.	3.9	6
422	Receiver operating characteristic analysis of sphincter electromyography for parkinsonian syndrome. Neurourology and Urodynamics, 2012, 31, 1128-1134.	1.5	24
423	Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report. Journal of Neurology, 2012, 259, 980-981.	3.6	6
424	Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes. Journal of Neurology, 2012, 259, 1181-1190.	3.6	92
425	Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation. Brain Research, 2012, 1436, 137-146.	2.2	40
426	Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 140-143.	2.1	86
427	Distal motor axonal dysfunction in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2011, 302, 58-62.	0.6	16
428	Involvement of pontine transverse and longitudinal fibers in multiple system atrophy: A tractography-based study. Journal of the Neurological Sciences, 2011, 303, 61-66.	0.6	18
429	Diminished emotional sweating in patients with limbic encephalitis. Journal of the Neurological Sciences, 2011, 306, 16-19.	0.6	10
430	Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica. Archives of Neurology, 2011, 68, 913.	4.5	40
431	Sensorimotor manifestations without autonomic symptoms in two siblings with TTR Val107 familial amyloid polyneuropathy. Clinical Neurology and Neurosurgery, 2011, 113, 139-141.	1.4	1

Altered axonal excitability properties in juvenile muscular atrophy of distal upper extremity (Hirayama) Tj ETQq0 0 0 rg BT /Overlock 10 T 14

#	Article	IF	CITATIONS
433	Activity-dependent changes in impulse conduction of single human motor axons: A stimulated single fiber electromyography study. Clinical Neurophysiology, 2011, 122, 2512-2517.	1.5	10
434	Dilated cardiomyopathy with centronuclear myopathy in a young male. International Journal of Cardiology, 2011, 150, 213-216.	1.7	4
435	Chronic inflammatory demyelinating polyneuropathy: Clinical subtypes and their correlation with electrophysiology. Clinical and Experimental Neuroimmunology, 2011, 2, 41-48.	1.0	25
436	POEMS syndrome with Guillan-Barre syndrome-like acute onset: a case report and review of neurological progression in 30 cases. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 678-680.	1.9	30
437	Detection of Bone Lesions by CT in POEMS Syndrome. Internal Medicine, 2011, 50, 1393-1396.	0.7	29
438	RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis. Nature Medicine, 2011, 17, 488-494.	30.7	100
439	Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: An immunohistochemical study. Experimental Neurology, 2011, 232, 149-153.	4.1	47
440	Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. Neurological Sciences, 2011, 32, 795-799.	1.9	11
441	Fisher Syndrome. Current Treatment Options in Neurology, 2011, 13, 71-78.	1.8	22
442	Pelvic organ dysfunction is more prevalent and severe in MSAâ€₽ compared to parkinson's disease. Neurourology and Urodynamics, 2011, 30, 102-107.	1.5	23
443	A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. Modern Rheumatology, 2011, 21, 561-562.	1.8	5
444	Isolated abducens and facial nerve palsies due to a facial collicular plaque in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 85-86.	1.9	13
445	Neuromuscular transmission is not impaired in axonal Guillain-Barre syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1174-1177.	1.9	10
446	Clumsy hand syndrome due to a localised cortical lesion in the primary sensory cortex in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 559-560.	1.9	2
447	Does Campylobacter jejuni infection elicit axonal or demyelinating Guillain-Barre syndrome, or both?. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 238-238.	1.9	10
448	Propagation: Prion-like mechanisms can explain spreading of motor neuronal death in amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1181-1182.	1.9	3
449	Urinary dysfunction in early and untreated Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1382-1386.	1.9	80
450	Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology, 2011, 77, 1532-1537.	1.1	153

#	Article	IF	CITATIONS
451	Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine. Case Reports in Medicine, 2011, 2011, 1-3.	0.7	2
452	A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. Modern Rheumatology, 2011, 21, 561-562.	1.8	3
453	Symptomatology of the Hand in Spinal Disorders and Amyotrophic Lateral Sclerosis. Spinal Surgery, 2011, 25, 248-251.	0.0	0
454	Multifocal Conduction Blocks in Sarcoid Peripheral Neuropathy. Internal Medicine, 2010, 49, 471-474.	0.7	6
455	15. Physiopathology and Treatment of Immunological Peripheral Neuropathy. Focusing on Guillain - Barré Syndrome The Journal of the Japanese Society of Internal Medicine, 2010, 99, 2325-2329.	0.0	Ο
456	B Cell Aplasia and Hypogammaglobulinemia after Carbamazepine Treatment. Internal Medicine, 2010, 49, 707-708.	0.7	13
457	Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis. Journal of Neuroimmunology, 2010, 218, 112-115.	2.3	22
458	Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurology, 2010, 10, 113.	1.8	30
459	Different responses to interferon betaâ€1b treatment in patients with neuromyelitis optica and multiple sclerosis. European Journal of Neurology, 2010, 17, 672-676.	3.3	89
460	Longâ€ŧerm regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2010, 15, 147-149.	3.1	11
461	Inward rectifying channels as new targets for treatment. Journal of Physiology, 2010, 588, 2523-2523.	2.9	Ο
462	Axonal Guillain-Barre syndrome is underestimated in Europe?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1063-1063.	1.9	6
463	Is tongue atrophy reversible in anti-MuSK myasthenia gravis? Six-year observation. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 701-702.	1.9	14
464	Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain, 2010, 133, 2058-2068.	7.6	72
465	Neuronal activities of forebrain structures with respect to bladder contraction in cats. Neuroscience Letters, 2010, 473, 42-47.	2.1	24
466	Spectral analysis of heart rate variability in patients with Machado-Joseph disease. Autonomic Neuroscience: Basic and Clinical, 2010, 154, 99-101.	2.8	9
467	Spinal myoclonus in the periscapular muscles after mastectomy assessed by FDG-PET. Clinical Neurology and Neurosurgery, 2010, 112, 527-529.	1.4	4
468	Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain. Clinical Neurophysiology, 2010, 121, 719-724.	1.5	22

#	Article	IF	CITATIONS
469	Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple Sclerosis Journal, 2010, 16, 1443-1452.	3.0	285
470	Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology, 2009, 73, 273-278.	1.1	318
471	NEUROLOGIC IMPROVEMENT AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN POEMS. Neurology, 2009, 73, 1165-1166.	1.1	4
472	Clinical predictors of mechanical ventilation in Fisher/Guillain-Barre overlap syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 60-64.	1.9	52
473	Physicochemical property changes of amino acid residues that accompany missense mutations in SCN1A affect epilepsy phenotype severity. Journal of Medical Genetics, 2009, 46, 671-679.	3.2	19
474	"Cloudâ€like enhancement―is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Annals of Neurology, 2009, 66, 425-428.	5.3	156
475	Chronic inflammatory demyelinating polyneuropathy sera inhibit axonal growth of mouse dorsal root ganglion neurons by activation of rhoâ€kinase. Annals of Neurology, 2009, 66, 694-697.	5.3	8
476	Preserved cardiac ¹²³ lâ€MIBG uptake and lack of severe autonomic dysfunction in a PARK9 patient. Movement Disorders, 2009, 24, 1403-1404.	3.9	4
477	Dopamine agonistâ€induced antecollis in Parkinson's disease. Movement Disorders, 2009, 24, 2408-2411.	3.9	36
478	Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease. Movement Disorders, 2009, 24, 2386-2390.	3.9	22
479	Differences in excitability properties of FDI and ADM motor axons. Muscle and Nerve, 2009, 39, 350-354.	2.2	53
480	Utility of trapezius EMG for diagnosis of amyotrophic lateral sclerosis. Muscle and Nerve, 2009, 39, 63-70.	2.2	56
481	Prevalence and mechanism of bladder dysfunction in Guillain–Barré Syndrome. Neurourology and Urodynamics, 2009, 28, 432-437.	1.5	43
482	Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. Journal of Neurology, 2009, 256, 2082-2084.	3.6	104
483	Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marrow Transplantation, 2009, 43, 739-740.	2.4	36
484	Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. Journal of the Peripheral Nervous System, 2009, 14, 151-158.	3.1	67
485	Neuropathic pain is associated with increased nodal persistent Na ⁺ currents in human diabetic neuropathy. Journal of the Peripheral Nervous System, 2009, 14, 279-284.	3.1	52
486	Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. Neuroscience, 2009, 162, 1333-1338.	2.3	25

#	Article	IF	CITATIONS
487	Relapse of POEMS syndrome without increased level of VEGF. Neuromuscular Disorders, 2009, 19, 740.	0.6	4
488	The effects of age, gender, and body mass index on amplitude of sensory nerve action potentials: Multivariate analyses. Clinical Neurophysiology, 2009, 120, 1683-1686.	1.5	53
489	Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. Journal of the Neurological Sciences, 2009, 287, 105-107.	0.6	43
490	Diffuse Neurosarcoidosis Involving Only the Leptomeninges of the Brainstem and Spinal Cord. Internal Medicine, 2009, 48, 1909-1913.	0.7	4
491	Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum. Journal of Neurology, 2008, 255, 674-682.	3.6	248
492	Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: Frequency, extent, and specificity. Muscle and Nerve, 2008, 37, 426-430.	2.2	144
493	Changes in Na ⁺ channel expression and nodal persistent Na ⁺ currents associated with peripheral nerve regeneration in mice. Muscle and Nerve, 2008, 37, 721-730.	2.2	21
494	Genetically confirmed Huntington's disease masquerading as motor neuron disease. Movement Disorders, 2008, 23, 748-751.	3.9	16
495	The ipsilateral corticoâ€spinal tract is activated after hemiparetic stroke. European Journal of Neurology, 2008, 15, 706-711.	3.3	30
496	Bickerstaff's brainstem encephalitis after an outbreak of Campylobacter jejuni enteritis. Journal of Neuroimmunology, 2008, 196, 143-146.	2.3	12
497	Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. Journal of Neuroimmunology, 2008, 196, 181-187.	2.3	102
498	Measurements of sweat response and skin vasomotor reflex for assessment of autonomic dysfunction in patients with diabetes. Journal of Diabetes and Its Complications, 2008, 22, 278-283.	2.3	17
499	Potassium channel antibody-associated encephalitis with hypothalamic lesions and intestinal pseudo-obstruction. Journal of the Neurological Sciences, 2008, 269, 176-179.	0.6	8
500	Development of Isaacs' syndrome following complete recovery of voltage-gated potassium channel antibody-associated limbic encephalitis. Journal of the Neurological Sciences, 2008, 275, 185-187.	0.6	12
501	Changes in excitability properties associated with axonal regeneration in human neuropathy and mouse Wallerian degeneration. Clinical Neurophysiology, 2008, 119, 1097-1105.	1.5	34
502	Peripheral nerve demyelination in multiple sclerosis. Clinical Neurophysiology, 2008, 119, 1829-1833.	1.5	42
503	Effects of age on excitability properties in human motor axons. Clinical Neurophysiology, 2008, 119, 2282-2286.	1.5	35
504	Sympathetic sweat responses and skin vasomotor reflexes in carpal tunnel syndrome. Clinical Neurology and Neurosurgery, 2008, 110, 691-695.	1.4	20

#	Article	IF	CITATIONS
505	<i>PARK9</i> -LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN <i>ATP13A2</i> AND CLINICAL PHENOTYPE. Neurology, 2008, 70, 1491-1493.	1.1	102
506	Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1255-1257.	1.9	86
507	Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology, 2008, 71, 1691-1695.	1.1	91
508	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. , 2008, , CD006828.		20
509	Restrictive usage of monoclonal immunoglobulin λ light chain germline in POEMS syndrome. Blood, 2008, 112, 836-839.	1.4	52
510	Pharmacologic Intervention in Axonal Excitability: In Vivo Assessment of Nodal Persistent Sodium Currents in Human Neuropathies. Current Molecular Pharmacology, 2008, 1, 61-67.	1.5	18
511	Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology, 2007, 68, 1144-1146.	1.1	128
512	Failure of Treatment with Anti-VEGF Monoclonal Antibody for Long-standing POEMS Syndrome. Internal Medicine, 2007, 46, 311-313.	0.7	57
513	Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clinical Neurology and Neurosurgery, 2007, 109, 858-861.	1.4	29
514	The effects of physiological fluctuation of serum potassium levels on excitability properties in healthy human motor axons. Clinical Neurophysiology, 2007, 118, 278-282.	1.5	22
515	ls excitation–contraction coupling impaired in myasthenia gravis?. Clinical Neurophysiology, 2007, 118, 1144-1148.	1.5	17
516	Median-radial sensory nerve comparative studies in the detection of median neuropathy at the wrist in diabetic patients. Clinical Neurophysiology, 2007, 118, 1405-1409.	1.5	23
517	Fisher/Gullain–Barré overlap syndrome in advanced AIDS. Journal of the Neurological Sciences, 2007, 258, 148-150.	0.6	26
518	Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia, 2007, 55, 746-757.	4.9	189
519	Sporadic case of spinocerebellar ataxia type 17: Treatment observations for managing urinary and psychotic symptoms. Movement Disorders, 2007, 22, 441-443.	3.9	11
520	Urinary retention and sympathetic sphincter obstruction in axonal Guillain–Barré syndrome. Muscle and Nerve, 2007, 35, 111-115.	2.2	17
521	Time course of axonal regeneration in acute motor axonal neuropathy. Muscle and Nerve, 2007, 35, 793-795.	2.2	22
522	Axonal Guillainâ€Barré syndrome: carbohydrate mimicry and pathophysiology. Journal of the Peripheral Nervous System, 2007, 12, 238-249.	3.1	74

#	Article	IF	CITATIONS
523	Anti-MuSK-positive myasthenia gravis: neuromuscular transmission failure in facial and limb muscles. Acta Neurologica Scandinavica, 2007, 115, 126-128.	2.1	22
524	Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle. Journal of Neuroimmunology, 2007, 189, 158-162.	2.3	19
525	Early prediction of prognosis in Guillain–Barré syndrome. Lancet Neurology, The, 2007, 6, 572-573.	10.2	3
526	Acute motor axonal neuropathy presenting with bowel, bladder, and erectile dysfunction. Journal of Neurology, 2007, 254, 250-252.	3.6	6
527	Guillain-Barré syndrome. Current Neurology and Neuroscience Reports, 2007, 7, 57-62.	4.2	48
528	Latent addition in human motor and sensory axons: Different site-dependent changes across the carpal tunnel related to persistent Na+ currents. Clinical Neurophysiology, 2006, 117, 810-814.	1.5	20
529	Nodal persistent Na+ currents in human diabetic nerves estimated by the technique of latent addition. Clinical Neurophysiology, 2006, 117, 815-820.	1.5	29
530	Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2006, 117, 1444-1448.	1.5	67
531	Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition. Clinical Neurophysiology, 2006, 117, 2451-2458.	1.5	63
532	Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain, 2006, 129, 953-962.	7.6	240
533	Concomitant chronic inflammatory demyelinating polyneuropathy and myasthenia gravis following cytomegalovirus infection. Journal of the Neurological Sciences, 2006, 240, 103-106.	0.6	20
534	Chronic Inflammatory Demyelinating Polyneuropathy Associated with Idiopathic Hemochromatosis. Internal Medicine, 2006, 45, 871-873.	0.7	16
535	Rho-kinase inhibition enhances axonal regeneration after peripheral nerve injury. Journal of the Peripheral Nervous System, 2006, 11, 217-224.	3.1	65
536	Bickerstaff brainstem encephalitis after heat stroke. Journal of Neurology, 2006, 253, 533-534.	3.6	5
537	Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. Journal of Neuroimmunology, 2006, 177, 201-208.	2.3	41
538	Electrophysiological subtypes and prognosis of childhood Guillain–Barré syndrome in Japan. Muscle and Nerve, 2006, 33, 766-770.	2.2	61
539	Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 66-70.	1.9	127
540	Leucocytoclastic vasculitic neuropathy diagnosed by biopsy of normal appearing skin. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 706-707.	1.9	7

#	Article	IF	CITATIONS
541	Voltage-gated potassium channel antibody-associated encephalitis with basal ganglia lesions. Neurology, 2006, 66, 1780-1781.	1.1	22
542	Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 185-188.	1.9	39
543	Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology, 2006, 66, 105-107.	1.1	115
544	Abnormal muscle responses in hemifacial spasm: F waves or trigeminal reflexes?. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 216-218.	1.9	11
545	Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics. Neurology, 2006, 66, 1545-1549.	1.1	27
546	Does Campylobacter jejuni infection elicit "demyelinating―Guillain–Barre̕syndrome?. Neurology, 2005, 64, 766-767.	1.1	1
547	HyperIgEaemia in patients with juvenile muscular atrophy of the distal upper extremity (Hirayama) Tj ETQq1 1 0.	784314 rg 1.9	gBT_/Overlock 26
548	Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 719-722.	1.9	87
549	Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barre̕syndrome. Neurology, 2005, 64, 856-860.	1.1	107
550	Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 714-718.	1.9	60
551	Strength-duration properties and glycemic control in human diabetic motor nerves. Clinical Neurophysiology, 2005, 116, 254-258.	1.5	34
552	The acute effects of glycemic control on nerve conduction in human diabetics. Clinical Neurophysiology, 2005, 116, 270-274.	1.5	35
553	The effects of mexiletine on excitability properties of human median motor axons. Clinical Neurophysiology, 2005, 116, 284-289.	1.5	29
554	Axonal potassium conductance and glycemic control in human diabetic nerves. Clinical Neurophysiology, 2005, 116, 1181-1187.	1.5	29
555	Superficial radial sensory nerve potentials in immune-mediated and diabetic neuropathies. Clinical Neurophysiology, 2005, 116, 2330-2333.	1.5	21
556	Putaminal hemorrhage disrupts thalamocortical projection to secondary somatosensory cortex: case report. Journal of the Neurological Sciences, 2005, 231, 81-83.	0.6	12
557	Low-frequency transcranial magnetic stimulation for epilepsia partialis continua due to cortical dysplasia. Journal of the Neurological Sciences, 2005, 234, 37-39.	0.6	76
558	Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease. Current Neurovascular Research, 2004, 1, 373-379.	1.1	27

#	Article	IF	CITATIONS
559	Does <i>Campylobacter jejuni</i> infection elicit "demyelinating―Guillain–Barre̕syndrome?. Neurology, 2004, 63, 529-533.	1.1	104
560	Sensory Nerve Conduction in Demyelinating and Axonal Guillain-Barré Syndromes. European Neurology, 2004, 51, 196-198.	1.4	39
561	Isolated Posterior Interosseous Nerve Palsy subsequent to <i>Campylobacter jejuni</i> Enteritis. European Neurology, 2004, 52, 63-64.	1.4	3
562	Trigeminal afferent input alters the excitability of facial motoneurons in hemifacial spasm. Neurology, 2004, 62, 1749-1752.	1.1	33
563	Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain, 2004, 127, 203-211.	7.6	83
564	The acute effects of glycemic control on axonal excitability in human diabetics. Annals of Neurology, 2004, 56, 462-467.	5.3	54
565	Threshold electrotonus in chronic inflammatory demyelinating polyneuropathy: Correlation with clinical profiles. Muscle and Nerve, 2004, 29, 28-37.	2.2	56
566	Excitability properties of human median axons measured at the motor point. Muscle and Nerve, 2004, 29, 227-233.	2.2	18
567	Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999–2000. Journal of the Neurological Sciences, 2004, 224, 43-47.	0.6	55
568	Increased ability of peripheral blood lymphocytes to degrade laminin in multiple sclerosis. Journal of the Neurological Sciences, 2004, 222, 7-11.	0.6	15
569	Epilepsia partialis continua as an isolated manifestation of motor cortical dysplasia. Journal of the Neurological Sciences, 2004, 225, 157-160.	0.6	17
570	Guillain-Barr?? Syndrome. Drugs, 2004, 64, 597-610.	10.9	201
571	Hyperglycemia alters refractory periods in human diabetic neuropathy. Clinical Neurophysiology, 2004, 115, 2525-2529.	1.5	31
572	Chapter 21 Conduction block in demyelinated axons precipitated by normally innocuous physiological processes. Supplements To Clinical Neurophysiology, 2004, 57, 191-194.	2.1	0
573	Leukocytoclastic-vasculitic neuropathy associated with chronic Epstein-Barr virus infection. Muscle and Nerve, 2003, 27, 113-116.	2.2	31
574	Raynaud's phenomenon in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 2003, 28, 252-253.	2.2	1
575	The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle and Nerve, 2003, 28, 683-689.	2.2	53
576	Anti-GM1b lgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection. Journal of the Neurological Sciences, 2003, 210, 41-45.	0.6	47

#	Article	IF	CITATIONS
577	Axonal Guillain–Barré syndrome associated with axonal Charcot–Marie–Tooth disease. Journal of the Neurological Sciences, 2003, 211, 93-97.	0.6	9
578	Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. Journal of the Neurological Sciences, 2003, 216, 179-182.	0.6	30
579	Shortened refractory periods in human diabetic neuropathy. Clinical Neurophysiology, 2003, 114, 169-170.	1.5	11
580	Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain–Barré syndrome. Brain, 2003, 126, 2279-2290.	7.6	367
581	Differences in patterns of progression in demyelinating and axonal Guillain–Barre̕syndromes. Neurology, 2003, 61, 471-474.	1.1	86
582	Muscle cramp in Machado-Joseph disease: Altered motor axonal excitability properties and mexiletine treatment. Brain, 2003, 126, 965-973.	7.6	105
583	Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 37-42.	1.9	82
584	Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 680-680.	1.9	41
585	The Acute Effects of Clycemic Control on Axonal Excitabiliy in Human Diabetic Nerves Internal Medicine, 2002, 41, 360-365.	0.7	27
586	Hyperreflexia in axonal Guillain–Barré syndrome subsequent to Campylobacter jejuni enteritis. Journal of the Neurological Sciences, 2002, 199, 89-92.	0.6	49
587	Successful immune treatment for non-paraneoplastic limbic encephalitis. Journal of the Neurological Sciences, 2002, 201, 85-88.	0.6	35
588	Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to Campylobacter jejuni enteritis. Journal of the Neurological Sciences, 2002, 205, 83-84.	0.6	25
589	Properties of human skin mechanoreceptors in peripheral neuropathy. Clinical Neurophysiology, 2002, 113, 310-315.	1.5	12
590	Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome. Journal of the Neurological Sciences, 2002, 195, 145-148.	0.6	16
591	Conduction block during and after ischaemia in chronic inflammatory demyelinating polyneuropathy. Brain, 2002, 125, 1850-1858.	7.6	30
592	Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. Annals of Neurology, 2002, 52, 180-187.	5.3	106
593	Effects of voluntary activity on the excitability of motor axons in the peroneal nerve. Muscle and Nerve, 2002, 25, 176-184.	2.2	50
594	Unilateral cranial and phrenic nerve involvement in axonal Guillain-Barré syndrome. Muscle and Nerve, 2002, 25, 297-299.	2.2	18

#	Article	IF	CITATIONS
595	Axonal hyperpolarization associated with acute hypokalemia: Multiple excitability measurements as indicators of the membrane potential of human axons. Muscle and Nerve, 2002, 26, 283-287.	2.2	38
596	Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle and Nerve, 2002, 26, 189-193.	2.2	110
597	Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle and Nerve, 2002, 26, 845-849.	2.2	72
598	Abnormalities of axonal excitability are not generalized in early multifocal motor neuropathy. Muscle and Nerve, 2002, 26, 769-776.	2.2	24
599	Autonomic function in demyelinating and axonal subtypes of Guillain-Barre syndrome. Acta Neurologica Scandinavica, 2002, 105, 44-50.	2.1	82
600	Responses of human sensory and motor axons to the release of ischaemia and to hyperpolarizing currents. Journal of Physiology, 2002, 541, 1025-1039.	2.9	67
601	Effects of voluntary activity on the excitability of motor axons in the peroneal nerve. Muscle and Nerve, 2002, 25, 176.	2.2	2
602	Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain, 2001, 124, 2439-2447.	7.6	79
603	Indicators of rapid clinical recovery in Guillain-Barre syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 560-562.	1.9	74
604	Serum levels of tumor necrosis factor–α in chronic inflammatory demyelinating polyneuropathy. Neurology, 2001, 56, 666-669.	1.1	80
605	Differences in responses of cutaneous afferents in the human median and sural nerves to ischemia. Muscle and Nerve, 2001, 24, 1503-1509.	2.2	13
606	Intravenous immunoglobulin therapy for Guillain-Barrï;½ syndrome with IgG anti-GM1 antibody. Muscle and Nerve, 2001, 24, 54-58.	2.2	70
607	Mechanisms of early and late recovery in acute motor axonal neuropathy. Muscle and Nerve, 2001, 24, 288-291.	2.2	22
608	Voluntary contraction impairs the refractory period of transmission in healthy human axons. Journal of Physiology, 2001, 531, 265-275.	2.9	29
609	Reversible Leukoencephalopathy Associated with Thrombotic Thrombocytopenic purpura. European Neurology, 2001, 45, 190-192.	1.4	5
610	Differences in accommodative properties of median and peroneal motor axons. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 372-376.	1.9	14
611	Clinical features and prognosis of Miller Fisher syndrome. Neurology, 2001, 56, 1104-1106.	1.1	365
612	Autonomic dysreflexia due to neurogenic bladder dysfunction; an unusual presentation of spinal cord sarcoidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 819-820.	1.9	10

#	Article	IF	CITATIONS
613	Excitability properties of median and peroneal motor axons. Muscle and Nerve, 2000, 23, 1365-1373.	2.2	69
614	Strength-duration properties and their voltage dependence as measures of a threshold conductance at the node of Ranvier of single motor axons. Muscle and Nerve, 2000, 23, 1719-1726.	2.2	18
615	Axonal Guillain-Barrï¿1⁄2 syndrome: Relation to anti-ganglioside antibodies andCampylobacter jejuni infection in Japan. Annals of Neurology, 2000, 48, 624-631.	5.3	308
616	Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 2000, 48, 826-832.	5.3	96
617	Accommodation to depolarizing and hyperpolarizing currents in cutaneous afferents of the human median and sural nerves. Journal of Physiology, 2000, 529, 483-492.	2.9	23
618	"Tactile―sensory nerve potentials elicited by air-puff stimulation: A microneurographic study. Neurology, 2000, 54, 762-762.	1.1	6
619	Haemophilus influenzae infection and Guillain-Barre syndrome. Brain, 2000, 123, 2171-2178.	7.6	110
620	Respiratory insufficiency in a patient with hereditary neuropathy with liability to pressure palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 110-111.	1.9	7
621	Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barre syndrome with antiganglioside antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 191-195.	1.9	69
622	Single unit responses of human cutaneous mechanoreceptors to air-puff stimulation. Clinical Neurophysiology, 2000, 111, 1577-1581.	1.5	16
623	Axonal Guillainâ€Barré syndrome: Relation to antiâ€ganglioside antibodies and Campylobacter jejuni infection in Japan. Annals of Neurology, 2000, 48, 624-631.	5.3	13
624	Activityâ€dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 2000, 48, 826-832.	5.3	2
625	Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Annals of Neurology, 2000, 48, 624-31.	5.3	81
626	Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 2000, 48, 826-32.	5.3	15
627	Hyperreflexia in Guillain-Barre syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 180-184.	1.9	89
628	n-Hexane Neuropathy Caused by Addictive Inhalation: Clinical and Electrophysiological Features. European Neurology, 1999, 41, 163-167.	1.4	29
629	lgG anti-GQ1b positive acute ataxia without ophthalmoplegia. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 668-670.	1.9	32
630	Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Annals of Neurology, 1999, 45, 533-536.	5.3	76

#	Article	IF	CITATIONS
631	Axonal involvement at the common entrapment sites in Guillain-Barr� syndrome with IgG anti-GM1 antibody. , 1999, 22, 840-845.		37
632	Dissociated small hand muscle involvement in amyotrophic lateral sclerosis detected by motor unit number estimates. , 1999, 22, 870-873.		80
633	Activity-dependent excitability changes in chronic inflammatory demyelinating polyneuropathy: A microneurographic study. , 1999, 22, 899-904.		11
634	Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. Journal of the Neurological Sciences, 1999, 168, 121-126.	0.6	90
635	Intravenous Methylcobalamin Treatment for Uremic and Diabetic Neuropathy in Chronic Hemodialysis Patients Internal Medicine, 1999, 38, 472-475.	0.7	74
636	Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain–Barre̕ syndrome. Neurology, 1999, 52, 1282-1282.	1.1	53
637	lgG Anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in guillain-barré syndrome. Annals of Neurology, 1998, 44, 202-208.	5.3	268
638	Demyelinating polyneuropathy with preferentially-proximal involvement. Clinical Neurology and Neurosurgery, 1998, 100, 53-55.	1.4	7
639	Sensory impairments in spinal multiple sclerosis: A combined clinical, magnetic resonance imaging and somatosensory evoked potential study. Clinical Neurology and Neurosurgery, 1998, 100, 199-204.	1.4	21
640	Two patterns of clinical recovery in Guillain-Barrel̀•syndrome with IgG anti-GM1 antibody. Neurology, 1998, 51, 1656-1660.	1.1	101
641	Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology, 1998, 50, 1179-1182.	1.1	28
642	Micturitional disturbance in patients with Guillain-Barre syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 649-653.	1.9	62
643	Long term melphalan-prednisolone chemotherapy for POEMS syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 385-387.	1.9	69
644	Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy. Neurology, 1997, 48, 874-877.	1.1	84
645	Slowly conducting, low-threshold components of sensory nerve potentials in peripheral neuropathy: A microneurographic study. , 1997, 20, 961-968.		4
646	Associated movement as a sequel to thoracotomy: Aberrant regeneration to the latissimus dorsi muscle. Movement Disorders, 1995, 10, 788-790.	3.9	7
647	Letters to the editor. Muscle and Nerve, 1993, 16, 1415-1424.	2.2	1
648	Neurodegenerative disorders affecting the autonomic nervous system: Pure autonomic failure and multiple system atrophy. Neurology and Clinical Neuroscience, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
649	Impaired neuromuscular transmission in facial muscles of amyotrophic lateral sclerosis: A singleâ€fiber electromyography study. Neurology and Clinical Neuroscience, 0, , .	0.4	1
650	Subacute combined degeneration of the spinal cord presenting with a longitudinally extensive spinal lesion with anterior funiculus involvement. Acta Neurologica Belgica, 0, , .	1.1	0